| human | Q5 |
| P6178 | Dimensions author ID | 01070711603.65 |
| P11723 | IRIS HUNIMED author ID | 00781 |
| P10057 | IRIS UNIMI author ID | 35537 |
| P9844 | IRIS UNIPV author ID | 18844 |
| P496 | ORCID iD | 0000-0002-7995-272X |
| P1153 | Scopus author ID | 11241441400 |
| P69 | educated at | Katholieke Universiteit Leuven | Q833670 |
| Institut Jules Bordet | Q964636 | ||
| P108 | employer | University of Milan | Q46210 |
| Humanitas Research Hospital | Q3803602 | ||
| Humanitas University | Q59386762 | ||
| P734 | family name | Personeni | Q65112040 |
| Personeni | Q65112040 | ||
| Personeni | Q65112040 | ||
| P735 | given name | Nicola | Q951924 |
| Nicola | Q951924 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q40224897 | A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma |
| Q41652822 | A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study |
| Q36779175 | Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. |
| Q34253748 | Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. |
| Q84179330 | Advanced colorectal liver metastases and surgery after preoperative chemotherapy: is response-based selection enough? |
| Q50103787 | Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases. |
| Q40619773 | Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications |
| Q102138487 | Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options |
| Q61054507 | Biomarkers in Hepatocellular Carcinoma--Letter |
| Q42364897 | Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. |
| Q52953584 | Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. |
| Q46884385 | Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer |
| Q93016751 | Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma |
| Q50978599 | Diagnostic accuracy of ¹¹C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma. |
| Q61054481 | Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study |
| Q61054490 | Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? |
| Q79394028 | Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib: does intratumoral heterogeneity matter? |
| Q83118938 | Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity |
| Q53550371 | FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study. |
| Q61054511 | Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection |
| Q38450375 | HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma |
| Q47597081 | Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipies |
| Q61054495 | Hepatocellular Carcinoma: A Global Disease in Need of Individualized Treatment Strategies |
| Q97560954 | Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade |
| Q43760313 | Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells |
| Q36528345 | KRAS mutation in lung metastases from colorectal cancer: prognostic implications |
| Q46903224 | KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab |
| Q61805290 | Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date |
| Q43508188 | Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. |
| Q112312725 | NASH limits anti-tumour surveillance in immunotherapy-treated HCC |
| Q79843530 | Outcome prediction to erlotinib in gastroesophageal adenocarcinomas: can we improve epidermal growth factor receptor and phospho-AKT testing? |
| Q46381917 | PD-019ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA). |
| Q43010373 | Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy |
| Q41942214 | Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma |
| Q52682078 | Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? |
| Q38674803 | Regorafenib for the treatment of unresectable hepatocellular carcinoma. |
| Q55600804 | Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications. |
| Q103036890 | SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS |
| Q61054485 | Shaping the landscape of immune oncology in hepatocellular carcinoma |
| Q40215577 | Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater! |
| Q43211029 | Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. |
| Q34196471 | Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach |
| Q92308453 | The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine |
| Q46893706 | The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer. |
| Q56384328 | Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study |
| Q38062681 | Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. |
| Q39466467 | Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma |
| Q37687269 | Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib |
| Q53097045 | Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. |
Search more.